Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy

  • Technology appraisal guidance
  • TA992
  • Published: 
Commercial discussions have concluded and the appraisal has resumed. Final Draft Guidance has been issued.